<p>Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) 被 16 位分析師給予&#34;中等買入&#34;的平均評級，MarketBeat Ratings 報告稱。四位研究分析師給予該股票持有評級，十一位給予買入評級，一位給予強烈買入評級。過去一年更新股票覆蓋的經紀人中，平均 1 年價格目標為 75.56 美元。</p>
<ul>
<li>Beam Therapeutics 因基因療法許可支付而大幅上漲</li>
</ul>
<p>近期有多位股票分析師對該股發表意見。瑞銀集團將 Apellis Pharmaceuticals 的目標股價從 89.00 美元下調至 85.00 美元，並在 5 月 8 日星期三的研究報告中為該公司設定了&#34;買入&#34;評級。摩根大通將 Apellis Pharmaceuticals 的股價目標從 78.00 美元上調至 79.00 美元，並在 3 月 6 日星期三的研究報告中為該股設定了&#34;超重&#34;評級。Piper Sandler 在 5 月 31 日星期五對 Apellis Pharmaceuticals 的股票進行了覆蓋。他們給出了&#34;中性&#34;評級，併為該公司設定了 46.00 美元的目標股價。富國銀行在 5 月 23 日星期四的報告中將 Apellis Pharmaceuticals 的目標股價從 57.00 美元下調至 48.00 美元，併為該公司設定了&#34;等權重&#34;評級。最後，花旗集團在 5 月 8 日星期三的報告中將 Apellis Pharmaceuticals 的股價目標從 67.00 美元下調至 60.00 美元，併為該公司設定了&#34;買入&#34;評級。</p>
<p><strong>查看我們對 APLS 的最新分析</strong></p>
<h2>Apellis Pharmaceuticals 股價下跌 7.6%</h2>
<ul>
<li>小市值股是市場下跌的前兆嗎？</li>
</ul>
<p>APLS 股票週五開盤價為 38.36 美元。該公司的市值為 46.6 億美元，市盈率為-11.09，貝塔係數為 0.95。Apellis Pharmaceuticals 的一年最低價為 19.83 美元，最高價為 92.22 美元。該公司的 50 日移動平均股價為 42.60 美元，200 日移動平均股價為 54.82 美元。公司的資產負債比為 0.35，流動比率為 3.77，速動比率為 3.02。</p>
<p>Apellis Pharmaceuticals (NASDAQ: APLS) 在 5 月 7 日星期二公佈了其財報。該公司本季度每股虧損為 0.54 美元，符合市場預期。本季度公司營收為 1.7233 億美元，超過分析師預期的 1.6337 億美元。Apellis Pharmaceuticals 的淨利潤率為-79.67%，淨資產回報率為-160.77%。Apellis Pharmaceuticals 的季度營收同比增長 284.3%。去年同期，該公司每股虧損為 1.56 美元。賣方分析師預計，Apellis Pharmaceuticals 本財年的每股收益將為-1.1 美元。</p>
<h2>內部交易活動</h2>
<p>在其他 Apellis Pharmaceuticals 的消息中，首席財務官 Timothy Eugene Sullivan 於 4 月 1 日星期一出售了該公司股票的 4,000 股。股票均價為 58.66 美元，總交易額為 234,640.00 美元。此次交易後，首席財務官現持有公司股票 93,338 股，價值約 5,475,207.08 美元。該交易已在美國證券交易委員會的法律文件中披露，可通過 SEC 網站查閲。此外，內部人員 Pascal Deschatelets 於 4 月 8 日星期一以 54.17 美元的均價出售了公司的 69,107 股股票。交易總額為 3,743,526.19 美元。該內部人員現直接持有公司 1,115,983 股股票，價值 60,452,799.11 美元。此次交易的披露信息可在此處找到。上一季度，內部人員共出售了價值 8,771,758 美元的公司股票 189,014 股。目前公司股份的 6.80% 由公司內部人員持有。</p>
<h2>Apellis Pharmaceuticals 的機構交易</h2>
<p>近期，一些大型投資者對該公司的持股進行了調整。先鋒集團在第四季度將其在 Apellis Pharmaceuticals 的持股比例提高了 0.9%。先鋒集團現在擁有該公司的 9,555,678 股股票，價值 572,003,000 美元，在此期間增持了 85,701 股。Price T Rowe Associates Inc. MD 在第四季度將其在 Apellis Pharmaceuticals 的持股比例提高了 38.0%。Price T Rowe Associates Inc. MD 現在擁有該公司的 2,460,339 股股票，價值 147,277,000 美元，在此期間增持了 677,098 股。Assenagon Asset Management S.A.在第四季度將其在 Apellis Pharmaceuticals 的持股比例提高了 109.6%。Assenagon Asset Management S.A.現在擁有該公司的 2,145,004 股股票，價值 128,400,000 美元，在此期間增持了 1,121,497 股。Polar Capital Holdings Plc 在第三季度將其在 Apellis Pharmaceuticals 的持股比例提高了 126.6%。Polar Capital Holdings Plc 現在擁有該公司的 1,053,875 股股票，價值 40,089,000 美元，在此期間增持了 588,875 股。最後，挪威國家銀行在第四季度新建了一個 Apellis Pharmaceuticals 的持倉，價值 56,640,000 美元。96.29% 的股份由對沖基金和其他機構投資者持有。</p>
<h2>Apellis Pharmaceuticals 公司簡介（獲取免費報告）</h2>
<p>Apellis Pharmaceuticals, Inc.是一家處於商業階段的生物製藥公司，專注於通過抑制補體系統來發現、開發和商業化治療化合物，用於治療自身免疫性和炎症性疾病。該公司提供 EMPAVELI 用於治療週期性夜間血紅蛋白尿、C3 腎小球病和免疫複合物膜增生性腎小球腎炎，以及造血幹細胞移植相關的血栓性微血管病; 以及 SYFOVRE 用於治療與年齡相關性黃斑變性和地理性萎縮症（GA）相關的地理性萎縮症。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們比 Apellis Pharmaceuticals 更喜歡的股票</li>
<li>如何投資保險公司：指南</li>
<li>高通股票：儘管波動性，AI 驅動增長</li>
<li>Russell 2000 指數，投資者如何利用它進行盈利交易</li>
<li>Salesforce 股票：會議總結，AI 聚焦和預測</li>
<li>頂級生物科技股票：探索創新機會</li>
<li>CAVA 是否過度擴張？仔細研究這隻高飛股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw"/></p>
<p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ Operation Replace Biden is a Go（來自 Freeport Society）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg5"/></p>
<h2>現在是否值得投資$1,000 在 Apellis Pharmaceuticals？</h2>
<p>在考慮投資 Apellis Pharmaceuticals 之前，您需要聽到這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户現在購買的股票清單... Apellis Pharmaceuticals 不在其中。</p>
<p>雖然 Apellis Pharmaceuticals 目前在分析師中具有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

APLS

<p>Apellis Pharmaceuticals, Inc.收到了分析師的 “中等買入” 評級。該股票被十一位分析師評為買入，四位分析師評為持有。該股票的平均目標價格為 75.56 美元。公司上個季度的財務結果顯示每股虧損 0.54 美元，符合預期。內部人士已經大量出售公司股票</p>

<p>Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has been given an average rating of &#34;Moderate Buy&#34; by the sixteen analysts that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $75.56.</p>
<ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) 被 16 位分析師給予&#34;中等買入&#34;的平均評級，MarketBeat Ratings 報告稱。四位研究分析師給予該股票持有評級，十一位給予買入評級，一位給予強烈買入評級。過去一年更新股票覆蓋的經紀人中，平均 1 年價格目標為 75.56 美元。</p>
<ul>
<li>Beam Therapeutics 因基因療法許可支付而大幅上漲</li>
</ul>
</div><p>Several equities analysts recently weighed in on the stock. UBS Group cut their target price on shares of Apellis Pharmaceuticals from $89.00 to $85.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, May 8th. JPMorgan Chase &amp; Co. lifted their price objective on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, March 6th. Piper Sandler began coverage on shares of Apellis Pharmaceuticals in a report on Friday, May 31st. They issued a &#34;neutral&#34; rating and a $46.00 target price for the company. Wells Fargo &amp; Company lowered their target price on shares of Apellis Pharmaceuticals from $57.00 to $48.00 and set an &#34;equal weight&#34; rating for the company in a report on Thursday, May 23rd. Finally, Citigroup decreased their price objective on shares of Apellis Pharmaceuticals from $67.00 to $60.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, May 8th.</p>
<div class="lb-trans"><p>近期有多位股票分析師對該股發表意見。瑞銀集團將 Apellis Pharmaceuticals 的目標股價從 89.00 美元下調至 85.00 美元，並在 5 月 8 日星期三的研究報告中為該公司設定了&#34;買入&#34;評級。摩根大通將 Apellis Pharmaceuticals 的股價目標從 78.00 美元上調至 79.00 美元，並在 3 月 6 日星期三的研究報告中為該股設定了&#34;超重&#34;評級。Piper Sandler 在 5 月 31 日星期五對 Apellis Pharmaceuticals 的股票進行了覆蓋。他們給出了&#34;中性&#34;評級，併為該公司設定了 46.00 美元的目標股價。富國銀行在 5 月 23 日星期四的報告中將 Apellis Pharmaceuticals 的目標股價從 57.00 美元下調至 48.00 美元，併為該公司設定了&#34;等權重&#34;評級。最後，花旗集團在 5 月 8 日星期三的報告中將 Apellis Pharmaceuticals 的股價目標從 67.00 美元下調至 60.00 美元，併為該公司設定了&#34;買入&#34;評級。</p>
</div><p><strong>View Our Latest Analysis on APLS</strong></p>
<div class="lb-trans"><p><strong>查看我們對 APLS 的最新分析</strong></p>
</div><h2>Apellis Pharmaceuticals Stock Down 7.6 %</h2>
<ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 股價下跌 7.6%</h2>
<ul>
<li>小市值股是市場下跌的前兆嗎？</li>
</ul>
</div><p>Shares of APLS stock opened at $38.36 on Friday. The company has a market capitalization of $4.66 billion, a price-to-earnings ratio of -11.09 and a beta of 0.95. Apellis Pharmaceuticals has a one year low of $19.83 and a one year high of $92.22. The company's fifty day moving average price is $42.60 and its 200-day moving average price is $54.82. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.77 and a quick ratio of 3.02.</p>
<div class="lb-trans"><p>APLS 股票週五開盤價為 38.36 美元。該公司的市值為 46.6 億美元，市盈率為-11.09，貝塔係數為 0.95。Apellis Pharmaceuticals 的一年最低價為 19.83 美元，最高價為 92.22 美元。該公司的 50 日移動平均股價為 42.60 美元，200 日移動平均股價為 54.82 美元。公司的資產負債比為 0.35，流動比率為 3.77，速動比率為 3.02。</p>
</div><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, meeting the consensus estimate of ($0.54). The company had revenue of $172.33 million during the quarter, compared to analysts' expectations of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative return on equity of 160.77%. Apellis Pharmaceuticals's quarterly revenue was up 284.3% on a year-over-year basis. During the same period last year, the company posted ($1.56) earnings per share. Sell-side analysts expect that Apellis Pharmaceuticals will post -1.1 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals (NASDAQ: APLS) 在 5 月 7 日星期二公佈了其財報。該公司本季度每股虧損為 0.54 美元，符合市場預期。本季度公司營收為 1.7233 億美元，超過分析師預期的 1.6337 億美元。Apellis Pharmaceuticals 的淨利潤率為-79.67%，淨資產回報率為-160.77%。Apellis Pharmaceuticals 的季度營收同比增長 284.3%。去年同期，該公司每股虧損為 1.56 美元。賣方分析師預計，Apellis Pharmaceuticals 本財年的每股收益將為-1.1 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部交易活動</h2>
</div><p>In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 4,000 shares of the business's stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $58.66, for a total transaction of $234,640.00. Following the sale, the chief financial officer now owns 93,338 shares of the company's stock, valued at approximately $5,475,207.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 4,000 shares of the business's stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $58.66, for a total transaction of $234,640.00. Following the sale, the chief financial officer now owns 93,338 shares of the company's stock, valued at approximately $5,475,207.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Pascal Deschatelets sold 69,107 shares of the company's stock in a transaction on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the sale, the insider now directly owns 1,115,983 shares in the company, valued at $60,452,799.11. The disclosure for this sale can be found here. In the last quarter, insiders sold 189,014 shares of company stock worth $8,771,758. 6.80% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Apellis Pharmaceuticals 的消息中，首席財務官 Timothy Eugene Sullivan 於 4 月 1 日星期一出售了該公司股票的 4,000 股。股票均價為 58.66 美元，總交易額為 234,640.00 美元。此次交易後，首席財務官現持有公司股票 93,338 股，價值約 5,475,207.08 美元。該交易已在美國證券交易委員會的法律文件中披露，可通過 SEC 網站查閲。此外，內部人員 Pascal Deschatelets 於 4 月 8 日星期一以 54.17 美元的均價出售了公司的 69,107 股股票。交易總額為 3,743,526.19 美元。該內部人員現直接持有公司 1,115,983 股股票，價值 60,452,799.11 美元。此次交易的披露信息可在此處找到。上一季度，內部人員共出售了價值 8,771,758 美元的公司股票 189,014 股。目前公司股份的 6.80% 由公司內部人員持有。</p>
</div><h2>Institutional Trading of Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 的機構交易</h2>
</div><p>Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in shares of Apellis Pharmaceuticals by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company's stock valued at $572,003,000 after purchasing an additional 85,701 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Apellis Pharmaceuticals by 38.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company's stock valued at $147,277,000 after purchasing an additional 677,098 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of Apellis Pharmaceuticals by 109.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company's stock valued at $128,400,000 after purchasing an additional 1,121,497 shares during the period. Polar Capital Holdings Plc lifted its stake in shares of Apellis Pharmaceuticals by 126.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company's stock valued at $40,089,000 after purchasing an additional 588,875 shares during the period. Finally, Norges Bank acquired a new position in Apellis Pharmaceuticals during the fourth quarter worth $56,640,000. 96.29% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>近期，一些大型投資者對該公司的持股進行了調整。先鋒集團在第四季度將其在 Apellis Pharmaceuticals 的持股比例提高了 0.9%。先鋒集團現在擁有該公司的 9,555,678 股股票，價值 572,003,000 美元，在此期間增持了 85,701 股。Price T Rowe Associates Inc. MD 在第四季度將其在 Apellis Pharmaceuticals 的持股比例提高了 38.0%。Price T Rowe Associates Inc. MD 現在擁有該公司的 2,460,339 股股票，價值 147,277,000 美元，在此期間增持了 677,098 股。Assenagon Asset Management S.A.在第四季度將其在 Apellis Pharmaceuticals 的持股比例提高了 109.6%。Assenagon Asset Management S.A.現在擁有該公司的 2,145,004 股股票，價值 128,400,000 美元，在此期間增持了 1,121,497 股。Polar Capital Holdings Plc 在第三季度將其在 Apellis Pharmaceuticals 的持股比例提高了 126.6%。Polar Capital Holdings Plc 現在擁有該公司的 1,053,875 股股票，價值 40,089,000 美元，在此期間增持了 588,875 股。最後，挪威國家銀行在第四季度新建了一個 Apellis Pharmaceuticals 的持倉，價值 56,640,000 美元。96.29% 的股份由對沖基金和其他機構投資者持有。</p>
</div><h2>Apellis Pharmaceuticals Company Profile (Get Free Report</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 公司簡介（獲取免費報告）</h2>
</div><p>Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.是一家處於商業階段的生物製藥公司，專注於通過抑制補體系統來發現、開發和商業化治療化合物，用於治療自身免疫性和炎症性疾病。該公司提供 EMPAVELI 用於治療週期性夜間血紅蛋白尿、C3 腎小球病和免疫複合物膜增生性腎小球腎炎，以及造血幹細胞移植相關的血栓性微血管病; 以及 SYFOVRE 用於治療與年齡相關性黃斑變性和地理性萎縮症（GA）相關的地理性萎縮症。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
<li>How to Invest in Insurance Companies: A Guide</li>
<li>Qualcomm Stock: AI-Powered Growth Despite Volatility</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>Salesforce Stock: Meeting Recap, AI Focus, and Forecast</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Is CAVA Overextended? A Closer Look at This High-Flying Stock</li>
</ul>
<div class="lb-trans"><h2>推薦故事</h2>
<ul>
<li>五隻我們比 Apellis Pharmaceuticals 更喜歡的股票</li>
<li>如何投資保險公司：指南</li>
<li>高通股票：儘管波動性，AI 驅動增長</li>
<li>Russell 2000 指數，投資者如何利用它進行盈利交易</li>
<li>Salesforce 股票：會議總結，AI 聚焦和預測</li>
<li>頂級生物科技股票：探索創新機會</li>
<li>CAVA 是否過度擴張？仔細研究這隻高飛股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=APLS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Operation Replace Biden is a Go (From The Freeport Society)(Ad)</p>
<div class="lb-trans"><p>→ Operation Replace Biden is a Go（來自 Freeport Society）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8589&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Apellis Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 在 Apellis Pharmaceuticals？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Apellis Pharmaceuticals 之前，您需要聽到這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户現在購買的股票清單... Apellis Pharmaceuticals 不在其中。</p>
</div><p>While Apellis Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Apellis Pharmaceuticals 目前在分析師中具有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) 獲得分析師一致推薦為 “適度買入”